Chronic Myeloid Leukemia


FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive... Continue Reading

Useful Definitions for Chronic Myelogenous Leukemia (CML) (November 16, 2016)

Blood stem cell: An immature cell from which other types of blood cells develop. Bone marrow: The soft, sponge-like tissue in the center of most bones where blood cells are made. Chromosomes: Long strands... Continue Reading

Discovery of Ezh2 May Represent New Treatment Option for Chronic Myelogenous Leukemia (November 3, 2016)

Each year in the United States, approximately 5,000 people are diagnosed with CML. Most cases of CML are characterized by a chromosomal abnormality—the Philadelphia chromosome—in which genetic material... Continue Reading

High Up-Front Costs Could Delay Access to Life-Saving Blood Cancer Drugs for Medicare Patients (October 18, 2016)

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients’ treatment with a novel class of targeted therapies, according to... Continue Reading

Pass It On: July is National Leukemia and Lymphoma Awareness Month (September 1, 2016)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia (April 7, 2015)

Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

SYNRIBO® Approved for use in Chronic Myeloid Leukemia (February 21, 2014)

The U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. SYNRIBO is indicated for adult patients with chronic phase (CP +0.28%, news)... Continue Reading

Iclusig Approved for CML and ALL (January 4, 2013)

The U.S. Food and Drug Administration (FDA) has approved Iclusig™ (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+... Continue Reading

Tasigna Superior to Gleevec for Philadelphia Chromosome-Positive CML (December 21, 2012)

Tasigna® (nilotinib) is superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), according to the results of two studies presented... Continue Reading

Synribo Approved for CML (November 8, 2012)

The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older... Continue Reading

Bosulif Approved for CML (September 26, 2012)

The U.S. Food and Drug Administration (FDA) has approved Bosulif® (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. The drug is... Continue Reading

Ponatinib Produces High Response Rates in CML (August 13, 2012)

Ponatinib, an investigational targeted agent, appears to be significantly effective in treatment-refractory chronic myeloid leukemia (CML) and produces early and lasting responses, according to the preliminary... Continue Reading

Caring for Yourself During Chemotherapy for Leukemia: How to Manage Hair Loss, Dry Skin, and Brittle Nails (June 3, 2012)

Chemotherapy can be effective treatment for cancer but may also cause physical side effects that may be uncomfortable and affect your appearance. These side effects, however, are manageable. Hair Loss Hair... Continue Reading

New Warning Added to Sprycel Label (October 17, 2011)

The US Food and Drug Administration (FDA) announced that Sprycel® (dasatinib) may increase the risk of a rare but serious condition known as pulmonary arterial hypertension. Sprycel is a targeted therapy... Continue Reading

Bosutinib Shows Promise for Second-Line CML Treatment (October 14, 2011)

Treatment with the investigational drug bosutinib produced promising rates of response among patients with chronic-phase chronic myeloid leukemia (CML) that had previously been treated with Gleevec® (imatinib).... Continue Reading

Tasigna Continues to Show Benefit for Newly Diagnosed CML (September 7, 2011)

According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS